

Michael L. Metzker
(last updated April 24, 2025)

I. General Biographical Information

a. Personal:

Home address: 12015 Surrey Lane, Houston, TX 77024
Date of birth: September 20, 1962
Citizenship: United States

b. Education:

1984 University of California — Davis, Davis, CA
B.S. — Biochemistry & Biophysics
1996 Baylor College of Medicine, Houston, TX
Ph.D. — Molecular & Human Genetics

c. Academic Appointments:

2014-to-2019 Adjunct Associate Professor, Department of Molecular & Human Genetics & Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX
2009-to-2019 Adjunct Associate Professor, Department of Chemistry, Rice University, Houston, TX
2009-to-2014 Associate Professor, Department of Molecular & Human Genetics & Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX
2009-to-2014 Adjunct Associate Professor, Cell & Molecular Biology, Baylor College of Medicine, Houston, TX
2001-to-2008 Adjunct Assistant Professor, Department of Chemistry, Rice University, Houston, TX
2000-to-2008 Adjunct Assistant Professor, Cell & Molecular Biology, Baylor College of Medicine, Houston, TX
1999-to-2008 Assistant Professor, Department of Molecular & Human Genetics & Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX

d. Corporate positions and other professional experiences:

2013-to-Present Founder, President & CEO, RedVault Biosciences, Houston TX
2022-to-2023 Co-founder & CTO, 454 Bio, Inc.
2012 Founder, CTO, LaserGen, Inc.
2010 Consulted with Law & Order SVU on the episode, *The Quickie*
2009 Appeared on ABC's *20/20* profiling Collin Co. HIV criminal case
2009 Collin Co. work appeared on *Oprah*
2007-to-2009 Expert witness for HIV criminal case, Collins Co., TX
2004 Expert witness for HIV criminal case, Thurston Co., WA

2003	Appeared on <i>truTV's</i> series <i>Forensics Files</i> in episode #152, "Shot of Vengeance"
2002-to-2012	Founder, President & CEO, LaserGen, Inc., Houston TX
1997-to-1999	Expert witness for HIV criminal case, Lafayette, LA
1996-to-1999	Senior Research Biologist, Merck Research Laboratories, West Point, PA
1987-to-1991	Associate Scientist, Applied Biosystems, Inc. (ABI), Foster City, CA
1984-to-1987	Research Chemist, Bio-Rad Laboratories; Richmond, CA
1983-to-1984	Laboratory Technician, Aerojet-General Corporation; Sacramento, CA

e. Prior Expert Experience

In the past five years, I have provided expert testimony at a Markman hearing, trial or deposition in the following cases:

- Plexxikon, Inc. v. Novartis Pharmaceuticals Corp., 4:17-cv-04405-HSG (EDL; on behalf of Plexxikon, Inc.)
- Guardant Health, Inc. v. Foundation Medicine, Inc. CA No. 17-1616 (LPS) (CJB, on behalf of Foundation Medicine, Inc.)
- ArcherDx, Inc. v. Qiagen Inc. CA 18-cv-01019-MN-CJB (on behalf of Qiagen)
- Illumina, Inc. v. Natera, Inc. CA 3:18-cv-1662-SI (on behalf of Natera)
- Illumina, Inc v. Complete Genomics, Inc. Case No. 20-cv-1465 (on behalf of Complete Genomics)
- Complete Genomics, Inc. v. Illumina, Inc & Illumina Cambridge, LTD. Case No. 19-970-MN (on behalf of Complete Genomics)
- Pillar Biosciences, Inc. v. Swift Biosciences, Inc. Case No. IPR2021-00401 (on behalf of Swift Biosciences)
- Ravgen, Inc. v. Ariosa Diagnostics, Inc.; Roche Sequencing Solutions, Inc.; Roche Molecular Systems, Inc. (collectively "Roche") Case No. 20-cv-1646 (on behalf of Roche)
- Illumina Cambridge Limited and Illumina Singapore Pte Limited ("Illumina") v. Comercial Rafer, S.L. and MGI Latvia Tech, SIA ("MGI"), Commercial Court of Barcelona, Spain, matter 249.1.4 1249/2020-3 (on behalf of MGI)
- Guardant Health, Inc. v. Natera, Inc., Case No. 3:21-cv-04062 (on behalf of Natera)
- DNA Genotek, Inc. v. Spectrum Solutions, Case No. 21-cv-0516 (on behalf of DNA Genotek)
- Twinstrand Biosciences, Inc v. Guardant Health, Inc., Case No. 1:21-cv-01126 (on behalf of Twinstrand Biosciences)
- The Trustees of the University of Pennsylvania and Regenxbio, Inc. v. Sarepta Therapeutics and Sarepta Therapeutics Three, Inc, Case No. 20-1226 (on behalf of The Trustees of the University of Pennsylvania and Regenxbio, Inc)
- Spectrum Solutions v. DNA Genotek, Inc., *Inter Partes* Review IPR2022-01347 (on behalf of DNA Genotek)

- Invitae Corp. v. Natera, Inc.; Case No. 1:21-cv-006699-LPS and 1:21-cv-01635-LPS, (on behalf of Natera); US District Court, District of Delaware
- Natera, Inc., v. Neogenomics Laboratories, Inc., Case No. 1:23-cv-629 (on behalf of Natera)
- 10x Genomics, Inc. & Harvard College v. Vizgen, Inc., Case No. 22-595-MFK (on behalf of Vizgen)

II. Research Information

a. Research Support

1 — Pending research support:

Technical description: RedVault proposes development of a low cost, rapid, and accurate POC assay for the detection of syphilis, chlamydia, and/or gonorrhea that could facilitate early detection, thus potentially reducing transmission and sequelae as well as improve therapeutic outcomes in the clinic.

Funding agency: NIH

Investigator relationship: PI: Michael Metzker

Proposed date of funding: 09/30/2025– 09/29/2026

Annual costs: \$308,803

Grant: Not assigned yet, titled, “Detection of small RNAs from urine samples of patients infected with syphilis, chlamydia, and/or gonorrhea using a single POC, multiplex target reporter construct (TRC) assay by lateral flow.”

2 — Completed research support:

Technical description: RedVault proposes development of a low cost, rapid, and accurate POC assay for the detection of chlamydia and gonorrhea that could facilitate early detection, thus potentially reducing transmission and sequelae as well as improve therapeutic outcomes in the clinic.

Funding agency: CDC

Investigator relationship: PI: Michael Metzker

Date of funding: 09/30/2023– 03/31/2025

Annual costs: \$299,928

Grant: 1R43PS005272-01-00, titled, “POC detection of chlamydia and gonorrhea small RNAs using a target reporter construct assay by lateral flow in urine surrogates.”

Technical description: RedVault proposed the study and sequencing of genomes that has led to amazing discoveries in forensics, history, and medicine. Previous methods associated with preparing a DNA sample for sequencing depend on computationally reconstructing small pieces of data to understand genomic structure and variations, which is time intensive, error prone, and not accurate enough for large scale genomic information. The research proposed here is oriented toward significantly improving the methods of sample preparation, which will lead to improved efficiency, accuracy, and reduced costs to sequence DNA, thereby making the technology more accessible to more people.

Funding agency: NIH/NCI

Investigator relationship: PI: Michael Metzker

Date of funding: 02/01/2019 – 04/31/2023

Annual costs: \$224,998

Grant: R43 CA232896-01A1, titled “Solid-phase replication of long template libraries for next-generation sequencing”

Technical description: RedVault Biosciences’ proposes an innovative approach to reliably interrogate plasma specimens for clinically relevant miRNAs. Successful development of this technology may deliver a fundamental advancement in the cancer screening, tumor surveillance, and miRNA research fields.

Funding agency: NIH/NCI

Investigator relationship: PI: Michael Metzker

Date of funding: 06/07/2016 – 03/06/2018

Annual costs: \$199,859

Grant: R43 CA200398-01A1, titled, “Digital Analysis of Plasma miRNA populations in Pancreatic Cancer.”

Technical description: RedVault Biosciences’ proposal here is oriented toward significantly improving the methods of sample preparation, which will lead to improved efficiency, accuracy, and reduced costs to sequence DNA.

Funding agency: NIH/NCI

Investigator relationship: PI: Michael Metzker

Date of funding: 01/14/2016 – 02/13/2017

Annual costs: \$146,801

Grant: R43 CA196134-01A1, titled, “Efficient Creation of Long-Template Libraries for Next-Generation Sequencing”

Technical description: The major goals of this project are to support sequencing and technology development in the areas of human genetics, cancer, the microbiome and comparative genomics.

Funding agency: NIH/NHGRI

Investigator relationship: Richard A. Gibbs; Co-Director Boerwinkle; co-PIs Muzny, Wheeler, Metzker, Worley

Date of funding: 11/01/2011 – 02/08/2015; effective end 02/08/14

Annual costs: \$20,119,270

Grant: U54 HG003273-09, titled, “The Human Genome Sequencing Center”

Technical description: This proposal represents a request for continued funding of the Mayo Clinic Pharmacogenomics Research Network (PGRN) grant, “Pharmacogenetics of Phase II Drug Metabolizing Enzymes.” The Mayo PGRN is an integrated, multidisciplinary, pharmacogenomic research effort that is based on a decades-long focus at Mayo on the pharmacogenetics of phase II (conjugating) drug metabolizing enzymes.

Funding agencies: NIGMS, NHLBI, NCI, NIDA, NICHD, NHGRI, NIMH, NIAMS, ORWH *Investigator*

relationship: Richard Weinshilboum; Co-PIs Gibbs, Metzker, Scherer

Date of funding: 7/01/10 to 06/30/15; effective end 02/08/14

Annual costs: \$425,709

Grant: 2U19GM061388-12, titled “Pharmacogenetics of Phase II Drug Metabolizing Enzymes”

Technical description: This proposal seeks to expand our existing scientific work on HIV forensic studies by developing a robust ‘pathogen toolkit’ for source identification across a range of biological agents

Funding agencies: National Institute of Justice
Investigator: Michael L. Metzker
Date of funding: 01/01/12 to 12/31/13
Annual costs: \$341,017
Grant: 2011-DN-BX-K534 titled, "Extending the Microbial Forensic Toolkit Through Whole Genome Sequencing and Statistical Phylogenomics"

Technical description: This Phase I SBIR grant application proposes three aims: (i) identify the most efficient NGS platform by sequencing *E. coli* MG1655 using six platforms, (ii), conduct mixing experiments using purified gram negative and gram positive bacteria using the platform selected in aim (i), and (iii) conduct mixing experiments described in aim (ii) in the presence of human blood to simulate animal wound models.

Funding agency: Office of the Secretary of Defense, Defense Health Program

Investigator relationship: David Hertzog; co-PI Metzker

Date of funding: 02/01/11 to 08/31/12

Annual costs: \$150,000 *Total costs:* \$150,000

Contract: W81XWH-12-C-0061, titled "Feasibility Study to Explore NGS Technologies in Pathogen Identification"

Technical description: The goal is to evaluate the feasibility of our next-generation, cyclic reversible termination (CRT) sequencing approach by targeting 1,000 candidate genes on highdensity oligonucleotide chips. *Funding agency:* NIH: NHGRI

Investigator: Michael L. Metzker

Date of funding: 08/01/08 to 05/31/11

Annual costs: \$230,250 *Total costs:* \$422,125

Grant: 1R21 HG004757, titled "Targeted CRT Sequencing of 1000 Genes in KPD Patients"

Technical description: The goal is to develop ultrafast sequencing-by-synthesis (SBS) technology that is practical on a genomic scale. *Funding agency:* NIH: NHGRI

Investigator: Michael L. Metzker

Date of funding: 10/01/04 to 09/30/08

Annual costs: \$468,575 *Total costs:* \$2,933,762

Grant: 1 R01 HG003573-01 titled, "Ultrafast SBS Method for large-Scale Human Resequencing"

Technical description: Development of a novel portable DNA sequencer for rapid identification of single nucleotide polymorphisms (SNPs) in common disease.

Funding agency: NIH: NHGRI

Investigator: Michael L. Metzker

Date of funding: 06/07/04 to 02/28/06

Annual costs: \$421,914 *Total costs:* \$532,761

Grant: 1 R41 HG003265-01 titled, "Development of a Portable PME DNA Sequencer"

Technical description: Development of novel FluoroBase dyes and associated nucleotide triphosphates, which have the potential to create sets of spectrally resolvable dye-terminators.

Special note: Originally awarded to Michael L. Metzker as STTR application: Grant converted in SBIR

Funding agency: NIH:NHGRI

Investigator relationship: Vladislav A. Litosh; co-PI Metzker
Date of funding: 07/11/03 to 12/31/05
Annual costs: \$213,064 *Total direct costs:* \$289,689
Grant: 1 R43 HG002632-01A1 titled, "Synthesis of FluoroBase Nucleotides for DNA Sequencing"

Technical description: The major goal of this project is to produce a draft sequence of the rhesus macaque and bovine genomes and extract maximal biological information from these data.

Funding agency: NIH: NHGRI

Investigator relationship: Richard A. Gibbs; co-Director Weinstock, co-PIs Muzny, Wheeler, Metzker, Worley

Date of funding: 11/10/03 to 10/31/06

Annual direct costs: \$21,028,110 *Total direct costs:* \$89,072,698

Grant: 1 U01 HG02051 titled, "Large Scale Sequencing at BCM-HGSC"

Technical description: The goal of this project is to generate a draft sequence of the genome of *Bos Taurus*.

Funding agency: USDA

Investigator relationship: Richard A. Gibbs; co-Director Weinstock, co-PIs Muzny, Wheeler, Metzker, Worley

Date of funding: 12/01/03 to 11/31/05

Annual direct costs: \$3,879,953 *Total direct costs:* \$7,853,612

Grant: TEXR-2003-05478 titled, "Bovine Genome Sequencing Project (BGSP)"

Technical description: Development of a novel multi-color fluorescent detection apparatus with potential application for direct detection of targeted regions from genomic DNA materials.

Funding agency: NIH: NHGRI

Investigator: Michael L. Metzker

Date of funding: 04/01/03 to 03/31/05

Annual costs: \$150,000 *Total costs:* \$250,000

Grant: 1 R21 HG002443-01A2, titled "Development of Fluorescent Detector for DNA Sequencing"

Technical description: Development of a novel DNA sequencing strategy by synthesis for application in high-throughput single nucleotide polymorphism (SNP) analysis.

Funding agency: NIH: NHGRI

Investigator: Michael L. Metzker

Date of funding: 09/30/03 to 03/31/05

Annual costs: \$310,504 *Total costs:* \$436,400

Grant: 1 R41 HG003072-01 titled, "Screening *Taq* Pol I Variants using 3'-O-Modified-dNTPs"

Technical description: Pilot project to synthesize and characterize modified nucleoside for potential activity against HIV-1.

Funding agency: Robert A. Welch Foundation

Investigator: Michael L. Metzker

Date of funding: 06/01/01 to 07/31/04

Annual costs: \$50,000 *Total costs:* \$158,000

Grant: Q-1518 titled, "Characterization of HIV-1 drug resistance using 3'-saturated nucleotides"

Technical description: Development of sixteen spectrally-resolved dyes for high-throughput nucleic acid detection such as DNA sequencing.

Funding agency: NIH: NHGRI

Investigator relationship: Mathew Mahindaratne; co-PI Metzker – special note: Originally awarded to Michael L. Metzker as STTR application and then was converted in SBIR. *Date of funding:* 07/21/03 to 06/30/05

Annual direct costs: \$214,000 *Total direct costs:* \$214,000

Grant: 1 R43 HG002567-01A2 titled, “Development of Novel Fluorescent Dyes for DNA Sequencing”

Technical description: The major goal of this project is to determine the genome sequence of the rat.

Funding agency: NIH: NHGRI/NHLBI

Investigator relationship: Richard A. Gibbs; co-Director Weinstock, co-PIs Muzny, Wheeler, Metzker, Worley

Date of funding: 02/27/01 to 02/26/04

Annual direct costs: \$10,976,914 *Total direct costs:* \$25,950,547

Grant: 1 U54 HG02345-02 titled, “Draft sequence of the rat genome”

Technical description: The major goal of this project is to prepare two types of extremely sensitive fluorescent label “cassettes” for DNA sequencing that may be used with both dye primer and dye terminator strategies. *Funding agency:* NIH: NHGRI

Investigator relationship: Kevin Burgess; co-PI Metzker

Date of funding: 09/06/01 to 07/31/05

Annual direct costs: \$38,296 *Total direct costs:* \$114,923

Grant: Competing Renewal FDN-S80093 titled, “Unnatural nucleotides for DNA sequencing”

Technical description: To develop and validate novel pooling-based methods for the rapid physical mapping of BAC libraries. *Funding agency:* NIH: NCRR

Investigator relationship: Aleksandar Milosavljevic; co-PI Metzker *Date*

of funding: 09/30/02 to 08/31/05

Annual direct costs: \$206,693 *Total direct costs:* \$612,721

Grant: 1 U01 RR18464-01 titled, “Clone pooling methods for physical mapping”

Technical description: The major goals of this project are extensive mapping and sequencing of the mouse genome. *Funding agency:* NIH: NHGRI

Investigator relationship: Richard A. Gibbs; co-Director Weinstock, co-PIs Muzny, Wheeler, Metzker, Worley

Date of funding: 09/30/99 to 09/30/03

Annual direct costs: \$5,316,551 *Total direct costs:* \$20,851,198

Grant: 1 U54 HG02139 titled, “Network for large-scale sequencing of the mouse genome”

Technical description: To produce a draft sequence of *D. pseudoobscura* with annotation and finishing of selected full-length cDNA and gene-rich regions.

Funding agency: NIH: NHGRI

Investigator relationship: Richard A. Gibbs; co-Director Weinstock, co-PIs Richards, Muzny, Wheeler, Metzker, Worley

Date of funding: 05/10/02 to 04/30/03

Annual direct costs: \$3,336,210 Total direct costs: \$3,336,210
Grant: 1 U01HG02570 titled, "Sequencing, annotation and assembly of a second Drosophila"

b. National Scientific Participation

1 — Editorial/Advisory Boards:

2003-to-2006 *Genome Research*, Cold Spring Harbor Laboratory Press
2006-to-2012 *Advances in Genome Biology & Technology Meeting*, Scientific advisor
2011-to-2013 Genome Canada: Advancing Technology Innovation through Discovery
(ATID) Advisory Committee

2 — Review panels:

Jul 2025 NIH: (DCAI-13): Small Business: Microbial Diagnostics, Detection and
Decontamination
Feb 2024 Panel Chair: (SBIR) contract – Topic 108: Development of Rapid POC
Diagnostics for *Treponema pallidum* (Phase II)
Jan 2022 Panel Chair: (SBIR) contract – Topic 108: Development of Rapid POC
Diagnostics for *Treponema pallidum* (Phase I)
Nov 2019 NIH: ZRG1 SBIR/STTR/R21/R03: Infectious disease diagnostics, methods
in sterilization & disinfection Study Section panels: IDM-V (12 & 19)
NIH: ZRG1 SBIR: Biomaterials, Delivery, and Nanotechnology Study
Section panel, ZRG1 BST-R (10)
Jul 2019 Chair, CIHR: Operating Grant CEEHRC (Epigenetics)
May 2019 Chair, CIHR: Operating Grant: Epigenetics Clinical Translation
Feb 2019 Invited expert on forensics, Arizona State University
Jan 2018 Chair, CEEHRC Phase II competition, Impact grants
Nov 2017 NASA Translational Research Institute Omics Panel
Jul 2017 CEEHRC Phase II: Platform Centres Renewal; Canadian Institutes of
Health Research (CIHR)
Mar 2017 CIHR: Project Grant: Spring 2017 competition
Jun 2016 NIH: Sequencing Technology Special Emphasis Panel, ZHG1 HGR-N (M1)
Mar 2016 Disruptive Innovation in Genomics (DIG) Competition, Genome Canada
Jan 2016 Chair: CIHR's Team Grant: CEEHRC (Epigenetics)
Jun 2015 Genome Canada Genomics Innovation Network Technology
May 2015 Development International Review Committee
Mar 2015 National Center for Advancing Translational Sciences (NCATS), Special
Emphasis Panel
Nov 2014 Genome Canada's Membership to the Genomics Innovation Network
and Core Operations Support Funds competition
Oct 2014 Genomics, Computational Biology and Technology (GCAT) study section
Jun 2014 Interdisciplinary Molecular Science and Training – Cell, Molecular, and
Computational Biology study section
Mar 2014 Genomics, Computational Biology and Technology (GCAT) study section;
Transformative research award review
Feb 2014 ISD study section, Bioengineering Sciences and Technologies

Jan 2014	NASA study section: "Differential Effects on Homozygous Twin Astronauts Associated with Differences in Exposure to Spaceflight Factors"
Dec 2013	ISD study section, Bioengineering Sciences and Technologies
May 2013	Partnerships for Enhanced Engagement in Research (PEER) Health, NICHD
Apr 2013	Terry Fox New Frontiers Program in Cancer Research
Apr 2013	Science & Technology Innovation Centers' Renewal, Genome Canada
Jan 2013	Canada-Japan CEEHRC Teams in Epigenetics of Stem Cells, CIHR, Co-chair
Aug 2012	Chair: Team Grant: CEEHRC - LOI committee.
Feb 2012	Chair: Epigenomics platform peer review committee, Canadian Institutes of Health research (CIHR)
Feb 2012	Chair: Epigenetics catalyst peer review committee, CIHR
Sep 2011	Ad hoc member of NIH Instrumentation and Systems Development (ISD) study section
Feb 2011	Science & Technology Innovation Center Competition Review: Genome Canada
Nov 2010	ATID Review: Genome Canada
Mar 2010	IDDRC P30 REVIEW, ZHD1-MRG-C (ID)
Oct 2009	Genomics, Computational Biology and technology study section, NIH
Jul 2009	DP3 Review, ZDK1 GRB-N(01), NIDDK
Jan 2009	Applied Genomics Research in Bioproducts or Crops (ABC), Genome Canada
Sep 2008	NCI Structural Biophysics Laboratory Site Visit, NCI
Nov 2007	Technology Development Competition, Genome Canada
2005-2007	Permanent member of NIH ISD study section
Apr 2007	Applied Emerging Technologies for Cancer Research, ZCA1 SRRB-4 (M1), NCI
Oct 2006	Applied Emerging Technologies for Cancer Research, ZCA1 SRRB-K (J1), NCI
Jun 2006	Innovative Technologies for the Molecular Analysis of Cancer, ZCA1 SRRBK (O1), NCI
Mar 2006	Applied Emerging Technologies for Cancer Research, ZCA1 SRRB-9 (M1), NCI
Oct 2005	ISD study section [ZRG1 ISD (01)], NIBIB
Oct 2005	Emerging Technologies for Cancer Research, ZCA1 SRRB-4 (J1), NCI
Jul 2005	ISD study section [ZRG1 ISD (01)], NIBIB
Jun 2005	Innovative Technologies for Cancer Research, ZCA1 SRRB-3 (O1), NCI
Mar 2005	ISD study section [ZRG1 ISD (01)], NIBIB
Mar 2005	Innovative Molecular Analysis Technology, ZCA1 SRRB-C (M2), NCI
Nov 2004	ISD study section, ZRG1 ISD (01), NIBIB
Jul 2004	Innovative Molecular Analysis Technology, ZCA1 SRRB-C (O1), NCI
Jul 2004	ISD study section, ZRG1 ISD (01), NIBIB
Jun 2004	Subcommittee E – Cancer Epidemiology, Prevention & Control study section, NCI-E RPRB (X1), NCI

Mar 2004	ISD study section, ZRG1 ISD (01), NIBIB
Dec 2003	Genome Technology & Cytogenetics (GT&C) study section, ZRG1 GNM (90), NHGRI
Oct 2003	Atopic Dermatitis & Vaccinia Network; Clinical Studies Consortium study section [ZAI1 CL-1 (C1), NIAID
Jul 2003	GT&C study section, ZRG1 GNM (90), NHGRI
Nov 2001	Genome study section, CSR-GNM, NHGRI
Jul 2001	Center for Scientific Review – Special Emphasis Panel (CSR-SEP) study section [ZRG1 SSS-Y], NHGRI
Jul 2001	Bioengineering Research Partnership study section [ZRG1 SSS-Y (02)], NHGRI
Apr 2001	CSR-SEP study section [ZRG1 SSS-Y (11) B], NHGRI
Mar 2001	Microbial Genome Project – study section, DOE
Nov 2000	CSR-SEP SBIR/STTR study section [ZRG1 SSS-Y (10)], NHGRI
Mar 2000	CSR-SEP SBIR/STTR study section [ZRG1 SSS-Y (01)], NHGRI
Nov 1999	CSR-SEP SBIR/STTR study section [ZRG1 SSS-Y (01)], NHGRI
Jul 1999	Technologies for Generation of Full-Length Mammalian cDNA study section [CA99-005], NCI
Jul 1999	CSR-SEP SBIR/STTR study section [ZRG1 SSS-Y (01)], NHGRI
Mar 1999	CSR-SEP SBIR/STTR study section [ZRG1 SSS-Y (01)], NHGRI
Mar 1998	SBIR/STTR Molecular Genetics study section [ZRG2 GNM O2B], NHGRI
Mar 1997	Biological & Physiological SEP study section [ZRG2 SSS-Y (15)], NHGRI

3 — Professional societies:

1996-to-present	American Association for the Advancement of Science
2000-to-present	American Chemical Society
2014-to-present	Texas Genetics Society

4 — Invited lectures, presentations, research seminars:

Apr 2016	Critical Path to TB Drug Regimens (CPRT) Workshop, Washington DC, Invited Speaker
May 2015	Advances in Next Generation Sequencing, Online, Keynote speaker
Mar 2013	ABRF- Satellite workshop, Palm Springs, CA; Invited Speaker
Jun 2012	American Society of Microbiology, San Francisco, CA; Invited Speaker
Jun 2012	Copenhagenomics, Copenhagen, Denmark, Invited Speaker
Feb 2012	Advances in Genome Biology & Technology, Marco Island, FL; Speaker
Apr 2011	Next-Gen Sequencing Conference, Boston, MA; Keynote Speaker
Apr 2011	Texas Association for Clinical Laboratory Science (TACLS), Austin, TX; Invited Speaker
Oct 2010	Centre de Regulació Genòmica (CRG) Symposium, Barcelona Spain, Invited Speaker
Jun 2010	ACS Meeting, San Diego, CA; Invited Speaker

May 2010	Next Generation Sequencing Workshop, Lübeck University, Germany; Invited Speaker
May 2010	Genomics Automation Conference, Boston, MA; Invited Speaker
Feb 2009	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
Jun 2008	Workshop on Genotyping-Tissue Expression (GTEx) Resource, NIH Invited Participant
Oct 2007	International Conference on Genomics, Shenzhen, China; Invited Speaker
Sep 2007	IBC's Discovery-2-Diagnostics Conference, Philadelphia, PA Invited Chair & Speaker
Feb 2007	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
Oct 2006	International Conference on Genomics, Hangzhou, China Invited Speaker
Sep 2006	Genomics of Hyperglycaemia, Elsinore, Denmark Invited Speaker
Feb 2006	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
May 2005	5 th Annual RECOMB Satellite meeting on DNA Sequencing Technologies and Computation, Stanford University; Invited Speaker
Feb 2005	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
Feb 2004	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
Jun 2003	BECON 2003 Symposium on Catalyzing Team Science, NIH Invited Speaker
Jan 2002	Agriculture Program Research General Session, Texas A&M University Invited Speaker
Oct 2001	Genome sequencing and Analysis Conference XIII, San Diego, CA Invited Speaker
Feb 2001	Advances in Genome Biology & Technology, Marco Island, FL Invited Speaker
May 2000	Second Follow-Up Workshop on Priority Setting for Mouse Genomics and Genetics Resources, NIH; Invited Participant
Mar 1998	Full-Length cDNA Cloning: A Workshop on Problems and Solutions, The Banbury Center, Cold Spring Harbor; Invited Participant
May 1997	Workshop on Complete cDNA Sequencing, NIH; Invited Participant

c. Publications

1 — Peer-reviewed articles and reviews:

1. Burgess K, Gibbs RA, **Metzker ML**, and Raghavachari R (1994) Synthesis of an Oxyamide Linked Nucleotide Dimer and Incorporation into Antisense Oligonucleotide Sequences, *J. Chem. Soc., Chem Commun.*, 915-916.

2. **Metzker ML**, Raghavachari R, Richards S, Civitello A, Burgess K, and Gibbs RA (1994) Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphates, *Nucleic Acids Res.* 22, 4259-4267.
3. **Metzker ML**, Allain KM, and Gibbs RA (1995) Accurate determination of DNA in agarose gels using the novel algorithm *GelScann(1.0)*, *Comput. Applic. Biosci.* 11, 187-194.
4. **Metzker ML**, Lu J and Gibbs RA (1996) Electrophoretically Uniform Fluorescent Dyes for Automated DNA Sequencing, *Science* 271: 1420-1422.
5. Ansari-Lari MA, Liu XM, **Metzker ML**, Rut AR and Gibbs RA (1997) The extent of genetic variation in the CCR5 gene. *Nature Genet.* 16: 221-222.
6. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren G, Andreasson, S Vujic, M Bergen AAB, McGarty-Dugan V, Figueroa D, Austin CP, **Metzker ML**, Caskey CT, and Wadelius C (1998) Identification of the gene responsible for Best macular dystrophy. *Nature Genet.* 19:241-247.
7. **Metzker ML**, Ansari-Lari MA Liu XL, Holder DJ, and Gibbs RA (1998) Quantitation of MixedBase Populations of HIV-1 Variants by Automated DNA Sequencing with BODIPY DyeLabeled Primers. *BioTechniques* 25:446-462.
8. Hey PJ, Twells RCJ, Phillips MS, Nakagawa Y, Brown SD, Kawaguchi Y, Cox R, Xie G, Dugan V, Hammond H, **Metzker ML**, Todd JA, and Hess JF (1998) Cloning of a novel member of the low-density lipoprotein receptor family. *Gene* 216:103-111.
9. Brown SD, Twells RCJ, Hey PJ, Cox RD, Levy ER, Soderman AR, **Metzker ML**, Caskey CT, Todd JA, and Hess JF (1998) Isolation and characterization of *LRP6*, a novel member of the low density lipoprotein receptor gene family. *Biochem. Biophys. Res. Commun.* 248:879-888.
10. **Metzker ML**, Raghavachari R, Burgess K, and Gibbs RA (1998) Elimination of residual natural nucleotides from 3'-O-modified-dNTP syntheses by enzymatic Mop-Up. *BioTechniques* 25:814-817.
11. Muzny DM, **Metzker ML**, Bouck J, Gorrell JH, Ding Y, Maxim E, and Gibbs RA (1998) Using BODIPY Dye-Primer Chemistry in Large-Scale Sequencing. *IEEE Engineering in Medicine and Biology* 88-93.
12. Allikmets R, Seddon JM, Bernstein PS, Hutchinson A, Sharma S, Gerrard B, Li W, **Metzker ML**, Wadelius C, Caskey CT, Dean M, and Petrukhin K (1999) Rare variants of the best disease gene in patients with age-related macular degeneration and other maculopathies. *Hum. Genet.* 104: 449-453.
13. Bai C, Connolly B, Liu X, Hilliard CA, Galloway SM, Sandig V, Liu Q, **Metzker ML**, Austin CP, and Caskey CT (2000). Overexpression of a new secreted member of tumor necrosis factor receptor family in gastrointestinal tract tumors. *Proc. Natl. Acad. Sci. USA* 97:1230-1235.
14. Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, **Metzker ML**, Savino R, Caskey CT (2000) Optimization of the helper-dependent adenovirus system for production and potency *in vivo*. *Proc. Natl. Acad. Sci. USA.* 97:1002-1007.
15. Bouck JB, **Metzker ML**, and Gibbs RA (2000) Shotgun sample sequence comparisons between mouse and human genomes. *Nature Genet.* 25:31-3.
16. Zhang K, Kniazeva M, Han M, Li W, Yu Z, Yang Z, Li Y, **Metzker ML**, Allikmets R, Zack DJ, Kakuk LE, Lagali PS, Wong PW, MacDonald IM, Sieving PA, Figueroa DJ, Austin CP, Gould RJ, Ayyagari R, and Petrukhin K (2001) A 5-bp deletion in *ELOVL4* is associated with two related forms of autosomal dominant macular dystrophy. *Nature Genet.* 27:89-93.
17. International Human Genome Sequencing Consortium: Baylor College of Medicine Human Genome Sequencing Center: Gibbs RA, Muzny DM Scherer SE, Bouck JB, Sodergren EJ,

- Worley KC, Rives CM, Gorrell JH, **Metzker ML**, Naylor SL, Kucherlapati RS, Nelson DL, and Weinstock GM (2001) Initial sequencing and analysis of the human genome. *Nature* 409:860-921.
18. Twells RC, **Metzker ML**, Brown SD, Cox R, Garey C, Hammond H, Hey PJ, Levy E, Nakagawa Y, Philips MS, Todd JA, and Hess JF. (2001) The sequence and gene characterization of a 400kb candidate region for *IDD4* on chromosome 11q13. *Genomics* 72:231-242.
 19. Dederich DA, Okwuonu G, Garner T, Denn A, Sutton A, Escotto M, Martindale A, Delgado O, Muzny DM, Gibbs RA and **Metzker ML** (2002) Glass Bead Purification of Plasmid Template DNA for High-Throughput Sequencing of Mammalian Genomes. *Nucleic Acids Res.* 30:e32
 20. **Metzker ML**, Mindell DP, Ptak RG, Gibbs RA, and Hillis DM (2002) Molecular Evidence of HIV-1 Transmission in a Louisiana Criminal Case. *Proc. Natl. Acad. Sci. USA* 99:14292-14297.
 21. Twells RCJ, Mein CA, Payne F, Veijola R, Gilbey M, Bright M, Timms A, Nakagawa Y, Snook H, Nutland S, Rance HE, Carr P, Dudbridge F, Cordell HJ, Cooper J, Tuomilehto-Wolf E, Tuomilehto J, Phillips M, **Metzker M**, Hess JF, Todd JA (2003) Linkage and association mapping of the LRP5 locus on chromosome 11q13 in type 1 diabetes. *Human Genet.* 113:99-105.
 22. Ueda H *et al.* (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 423:506-511.
 23. Thoresen LH, Jiao GS, Haaland WC, **Metzker ML**, and Burgess K (2003) Rigid, Conjugated, Fluoresceinated Thymidine Triphosphates: Syntheses and Polymerase Mediated Incorporation Into DNA. *Chem. Eur. J.* 9:4603-4610.
 24. Twells RCJ, Mein CA, Phillips MS, Hess JF, Veijola R, Gilbey M, Bright M, **Metzker ML**, Lie BA, Kingsnorth A, Gregory E, Nakagawa Y, Snook H, Wang WYS, Masters J, Johnson G, Eaves I, Howson JMM, Clayton D, Cordell HJ, Nutland S, Rance H, Carr P and Todd JA (2003) Haplotype Structure, LD Blocks, and Uneven Recombination Within the *LRP5* Gene. *Genome Res.* 13:845-855.
 25. International Human Genome Sequencing Consortium: Baylor College of Medicine Human Genome Sequencing Center (2004) Finishing the euchromatic sequence of the human genome. *Nature* 431:931-945.
 26. Gibbs RA, Weinstock GM, **Metzker ML et al.** (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. *Nature* 428:493-521.
 27. Richards S *et al.* (2005) Comparative genome sequencing of *Drosophila pseudoobscura*: chromosomal, gene, and cis-element evolution. *Genome Res.* 15:1-18.
 28. Ross MT *et al.* (2005) The DNA sequence of the human X chromosome. *Nature* 434:325-337.
 29. Lewis EK, Haaland WC, Nguyen F, Heller DA, Allen MJ, Macgregor RR, Berger CS, Willingham B, Burns LA, Scott GB, Kittrell C, Johnson BR, Curl RF, **Metzker ML** (2005) Color-blind fluorescence detection for four-color DNA sequencing *Proc. Natl. Acad. Sci. USA* 102:53465351.
 30. Fernandez R, Zhang Y, Pai S, **Metzker ML**, Schumacher A (2005) *I7Rn6* encodes a novel protein required for Clara cell function in mouse lung development. *Genetics* 172:389-399.
 31. **Metzker ML** (2005) Emerging Technologies in DNA Sequencing. *Genome Res.* 15:1767-1776.
 32. Scherer S *et al.* (2006) The Finished DNA Sequence of Human Chromosome 12. *Nature* 440 346-351.
 33. Muzny D *et al.* (2006) The DNA sequence, annotation and analysis of human chromosome 3. *Nature* 440:1194-1198

34. Jiao G-S, Thoresen LH, Kim TG, Haaland WC, Topp MR, Hochstrasser RM, **Metzker ML**, Burgess K (2006) Syntheses, photophysical properties, and applications of through-bond energy transfer cassettes for multiplexing in biotechnology. *Eur. J. Chem.* 12:7816-7826.
35. Wu W, Stupi BP, Litosh VA, Mansouri D, Farley D, Morris S, Metzker S, **Metzker ML** (2007) Termination of DNA synthesis by *N*⁶-alkylated, not 3'-*O*-alkylated, photocleavable 2'-deoxyadenosine triphosphates. *Nucleic Acids Res.* 35:6339-49.
36. **Metzker, ML** (2009) Sequencing in real time. *Nature Biotechnol.* 27:150-151.
37. Haaland WC, Scaduto DI, Maldonado, MR, Mansouri DL, Nalini R, Iyer D, Patel S, Guthikonda A, Hampe CS, Balasubramanyam A, **Metzker ML**. (2009) The "A-β-" subtype of Ketosis-Prone Diabetes (KPD) is not predominantly a monogenic diabetic syndrome. *Diabetes Care* 32:873877.
38. Church DM *et al.* (2009) Lineage-specific biology revealed by a finished genome assembly of the mouse. *PLoS Biol.* 5:e1000112
39. **Metzker ML**. (2010) Sequencing technologies — the next generation. *Nature Rev. Genet.* 11:31-46
40. The 1000 Genomes Project Consortium. (2010) A map of human genome variation from population-scale sequencing. *Nature* 467:1061-73.
41. Sudmant *et al.* Diversity of human copy number variation and multicopy genes. (2010) *Science* 330:641-646.
42. Scaduto DI, Brown JM, Haaland WC, Zwickl DJ, Hillis DM, **Metzker ML**. (2010) Source identification in two criminal cases using phylogenetic analysis of HIV-1 DNA sequences. *Proc Natl Acad Sci USA* 107:21242-21247.
43. Litosh VA, Wu W, Stupi BP, Wang J, Morris, SE, Hersh MN, **Metzker ML**. (2011) Improved nucleotide selectivity and termination of 3'-OH unblocked reversible terminators by molecular tuning of 2-nitrobenzyl alkylated HOMedU triphosphates. *Nucleic Acids Res.* 39:e39.
44. Leitner, T. **Metzker ML**, *et al.*, (2011) Guideline for HIV in court. *Nature* 473:284
45. Hertzog D, Hersh MN, **Metzker ML**. (2011) A high-performance, low-cost approach to next-generation sequencing. *BioOptics World*, Nov-Dec Issue.
46. Mills *et al.* Mapping copy number variation by population-scale genome sequencing. (2011) *Nature*, 470:59-65.
47. Danecek *et al.* (2011) The variant call format and VCFtools. *Bioinformatics*, 27:2156-2158.
48. Conrad *et al.*, (2011) Variation in genome-wide mutation rates within and between human families. *Nature Genet.* 43:712-714.
49. Gravel *et al.* (2011) Demographic history and rare allele sharing among human populations. *Proc. Natl. Acad. Sci. USA.* 108: 11983-11988.
50. Marth *et al.* (2011) The functional spectrum of low-frequency coding variation. *Genome Biol.* 12:R84.
51. Stupi BP, Li H, Wang J, Wu W, Morris SE, Litosh VA, Muniz J, Hersh MN, **Metzker ML**. (2012) Stereochemistry of benzylic carbon substitution coupled with ring modification of 2-nitrobenzyl groups as key determinants for fast-cleaving reversible terminators. *Angew. Chem. Int. Ed.*, 51: 1724-1727.
52. Clarke *et al.* (2012) The 1000 genomes project: data management and community access. *Nature Methods*, 9:459-462

53. Gardner AF, Wang J, Wu W, Karouby J, Li H, Stupi BS, Jack WE, Hersh MN, **Metzker ML** (2012) Improved fidelity and rapid incorporation kinetics of 3'-OH unblocked reversible terminators by Terminator DNA polymerase. *Nucleic Acids Res.*, 40:7404-7415.
54. Doyle VP, Andersen JJ, Nelson BJ, **Metzker ML**, Brown JM (2014) Untangling the influences of unmodeled evolutionary processes on phylogenetic signal in a forensically important HIV-1 transmission cluster. *Mol Phylogenet Evol.*, 75:126-137.
55. Redondo MJ, Muniz J, Rodriguez LM, Iyer D, Vaziri-Sani F, Haymond MW, Hampe CS, **Metzker ML**, Grant SFA, Balasubramanyam A. (2014) Association of *TCF7L2* Variation with Single Islet Autoantibody Expression in Children with Type 1 Diabetes. *BMJ Open Diabetes Res. Care*, 2:e000008.
56. Couturier J, Suliburk JW, Brown JM, Luke DJ, Agarwal N, Yu X, Nguyen C, Iyer D, Kozinetz CA Overbeek PA, **Metzker ML**, Balasubramanyam A, Lewis DE (2015) Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. *AIDS* 29:667-674.
57. Fujimoto K, Coghill LM, Weier CA, Hwang LY, Kim JY, Schneider JA, **Metzker ML**, Brown JM (2017) Lack of Support for Socially Connected HIV-1 Transmission Among Young Adult Black Men Who Have Sex with Men. *AIDS Res Hum Retroviruses*, 33(9):935-940.
58. Yang D, Patel S, Szlachcic WJ, Chmielowiec J, Scaduto D, Putluri N, Sreekumar A, Suliburk J, **Metzker M**, Balasubramanyam A, Borowiak M. (2021) Pancreatic differentiation of stem cells reveals pathogenesis of a syndrome of Ketosis-Prone Diabetes. *Diabetes*, 2021 Aug 3;db201293. doi: 10.2337/db20-1293. Online ahead of print.

2 — Book Chapters:

1. Caskey CT, Liu O, **Metzker ML**, Gerhold D, and Austin CP (1998) Functional Analysis of Human Genes. GENOMICS, Commercial Opportunities from a Scientific Revolution, p. 55-68. In GK Dixon, LG Copping, and D Livingstone (Eds.). Bios Scientific Publishers Ltd., Oxford.
2. **Metzker ML** and Caskey CT (2001) Polymerase chain reaction. In *Encyclopedia of Life Sciences*. Macmillan References Ltd., London.
3. **Metzker ML** and Caskey CT (2006) Polymerase chain reaction. In *Encyclopedia of Medical Devices and Instrumentation* by JG Webster (Ed.), Second edition, Volume 5, John Wiley & Sons, Inc., Hoboken, New Jersey.
4. **Metzker ML** (2006) Emerging Technologies in DNA Sequencing. In *Genomes, Cold Spring Harbor Monograph Series* by HE Sussman and MA Smit (Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
5. **Metzker ML** (2007) Advances in next-generation DNA sequencing technologies. In *Comparative Genomics: Basic and Applied Research* by JR Brown (Ed.), Taylor & Francis, Boca Raton, FL.
6. **Metzker ML** and Caskey CT (2009) Polymerase chain reaction. In *Encyclopedia of Life Sciences*. Macmillan References Ltd., London.
7. **Metzker ML** (2014) Polymerase chain reaction. In *Discoveries in Modern Science: Exploration, Invention, Technology*. Macmillan References Ltd., London.

3— Posters:

1. **Metzker ML** (2008) Sequencing technologies — the next generation. *Nature Reviews Genetics* and *Nature Genetics*, Invited Project — <http://www.nature.com/nrg/posters/sequencing/index.html>

d. US issued patents, US patent applications, EP Patents, PCT applications

1. Cathcart GR, Breenan-Marquez T, Bridgham JA, Golda G, Guiremand HA, Hane M, Hoff LB, Lachenmeier E, Kronick MN, Keith DH, Mayrand PE, **Metzker ML**, Mordan WJ, McBride LJ, Shigeura J, Ting CH, and Whiteley NM (1991) PCT Application No. WO 91/16675. Automated molecular biology laboratory; filed Apr 4, 1991.
2. Gibbs RA, Richards S, Civitello A, Burgess K, Raghavachari R, **Metzker ML** (1993) PCT Application No. WO 93/05183. Method and device for rapid DNA or RNA sequencing determination by a base addition sequencing scheme; filed Sep 9, 1991.
3. Cathcart GR, Breenan-Marquez T, Bridgham JA, Golda G, Guiremand HA, Hane M, Hoff LB, Lachenmeier E, Kronick MN, Keith DH, Mayrand PE, **Metzker ML**, Mordan WJ, McBride LJ, Shigeura J, Ting CH, and Whiteley NM (1995) US Patent 5,443,791. Automated molecular biology laboratory.
4. **Metzker ML** and Gibbs RA (1997) US Patent 5,614,386. Alternative dye-labeled primers for automated DNA sequencing.
5. **Metzker ML** and Gibbs RA (1997) PCT Application No. WO 97/00967 Alternative dye-labeled primers, ribonucleotides, deoxyribonucleotides and dideoxyribonucleotides dideoxyribonucleotides for automated DNA analysis and homogeneous amplification/ detection assays; filed June 21, 1996.
6. **Metzker ML** and Gibbs RA (1998) US Patent 5,728,529. Alternative dye-labeled ribonucleotides, deoxyribonucleotides and dideoxyribonucleotides for automated DNA analysis.
7. Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H, Hey P, Kawaguchi Y, Merriman TR, **Metzker ML**, Nakagawa Y, Phillips MS, Twells RCJ (1998) PCT Application No. WO 98/46743. Novel LDL-receptor; filed. Apr 15, 1998.
8. **Metzker ML** and Gibbs RA (1999) US Patent 5,861,287. Alternative dye-labeled primers for automated DNA sequencing.
9. **Metzker ML** and Gibbs RA (1999) US Patent 5,994,063. Substituted 4,4 difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogeneous amplification/ detection assays.
10. Petrukhin, K, Caskey, CT, **Metzker, ML**, Wadelius, C (1999) PCT Application No. WO 99/43695. Best's Macular Dystrophy gene; filed Feb 22, 1999.
11. Petrukhin K, Caskey CT, Li W, **Metzker ML** (2000) PCT Application No. WO 00/61606. Novel human voltage-gated potassium channel; filed Apr 14, 1999.
12. Liu XL, Bai C and **Metzker ML** (2001) PCT Application No. WO 01/42434. DNA molecules encoding human NHL a DNA helicase; filed Dec 9, 1999.
13. Todd JA, Twells RCJ, Hess JW, Hey P, Caskey CT, Hammond H, **Metzker ML** (2001) PCT Application No. WO 01/29213. Human Sit4 associated proteins like (SAPL) proteins and encoding genes; uses therefo.
14. Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H, Hey P, Kawaguchi Y, Merriman TR, **Metzker ML**, Nakagawa Y, Phillips MS, Twells, RCJ (2003) US Patent 6,545,137. Receptor.
15. Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H, Hey P, Kawaguchi Y, Merriman TR, **Metzker ML**, Nakagawa Y, Phillips MS, Twells RCJ (2003) US Patent 6,555,654. LDL-receptor.

16. **Metzker ML** (2003) US Patent Application Publication No. US2003/0180769. Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for 8-color DNA sequencing; filed Feb 5, 2003.
17. Scott GBI, Kittrell C, Curl RF, and **Metzker ML** (2003) PCT Application No. WO 03/021212. Pulsed-multiline excitation for color-blind fluorescence detection; filed Aug 28, 2002.
18. Liu XL, Bai C and **Metzker ML** (2004) US Patent 6,762,042. DNA molecules encoding human NHL a DNA helicase.
19. Scott GBI, Kittrell C, Curl RF, and **Metzker ML** (2006) US Patent 6,995,841. Pulsed-multiline excitation for color-blind fluorescence detection.
20. Petrukhin K, Caskey CT, **Metzker ML**, Wadelius C (2006) US Patent 7,005,290. Best's Macular Dystrophy gene.
21. Petrukhin K, Caskey CT, **Metzker ML**, Wadelius C (2006) US Patent Application Publication No. 2006/0105364. Best's Macular Dystrophy gene, filed Sep 27, 2006.
22. Petrukhin K, Caskey CT, Li W, **Metzker ML** (2006) European Patent EP 1 173 465 B1. Novel human voltage-gated potassium channel.
23. Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H, Hey P, Kawaguchi Y, Merriman TR, **Metzker ML**, Nakagawa Y, Phillips MS, Twells RCJ (2007) US Patent 7,244,577. Method of screening for modulator of LRP5 activity.
24. Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H, Hey P, Kawaguchi Y, Merriman TR, **Metzker ML**, Nakagawa Y, Phillips MS, Twells RCJ (2007) European Patent EP 0 988 379 B1. LDL-receptor.
25. Wu W, Litosh V, Stupi B, **Metzker ML**. (2008) PCT Application No. US2008/070749. Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing; filed: Dec 5, 2007.
26. Liu XL, Bai C and **Metzker ML** (2008) US Patent 7,361,491. DNA molecules encoding human NHL a DNA helicase.
27. Scott GBI, Kittrell C, Curl RF, and **Metzker ML** (2009) US Patent 7,511,811. Pulsed-multiline excitation for color-blind fluorescence detection.
28. Litosh V, Hersh M, Stupi B, Wu W, **Metzker ML**. PCT Application No. US2009/152353. Nucleotides and nucleosides and methods for their use in DNA sequencing. *Filed*: Jun 11, 2009.
29. Wu W, Litosh V, Stupi B, **Metzker ML**. (2011) US Patent 7,893,227. 3'OH unblocked nucleotides and nucleosides, base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing.
30. Wu W, Litosh V, Stupi B, **Metzker ML**. (2011) US Patent 7,897,737. 3'OH unblocked nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing.
31. Wu W, Litosh V, Stupi B, **Metzker ML**. (2011) US Patent 7,964,352. 3'OH unblocked nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing.
32. Lafferty WM, Beechem J, Hongye S, **Metzker ML** (2011) US Patent Application Publication No. 2011/0311963. Method and Apparatus for Addressable Flow Cells in Single Molecule Sequencing; filed March 16, 2011.
33. Lafferty WM, Beechem J, Hongye S, **Metzker ML** (2011) PCT Application No. WO/2011/116120. Method and Apparatus for Addressable Flow Cells in Single Molecule Sequencing; filed March 16, 2011.

34. Scott GBI, Kittrell C, Curl RF, and **Metzker ML** (2012) US Patent 8,089,628. Pulsed-multiline excitation for color-blind fluorescence detection.
35. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2012) US Patent 8,148,503. Labeled nucleotides and nucleosides and methods for their use in DNA sequencing.
36. Wu W, Litosh V, Stupi B, **Metzker ML**. (2012) US Patent 8,198,029. 3'OH unblocked nucleotides and nucleosides, base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing.
37. Wu W, Litosh V, Stupi B, **Metzker ML**. (2013) US Patent 8,361,727. 3'OH unblocked nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing.
38. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2013) US Patent 8,497,360. Nucleotides and nucleosides and methods for their use in DNA sequencing.
39. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2014) US Patent 8,887,905. Nucleotides and nucleosides and methods for their use in DNA sequencing.
40. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2014) US Patent 8,889,860. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
41. Wu W, Litosh V, Stupi B, **Metzker ML**. (2013) US Patent 8,969,535. Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing.
42. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2013) PCT Application No. 2013/040257. 5-methoxy 3'-OH Unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing; filed September 13, 2012.
43. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2015) US Patent 9,200,319. Nucleotides and nucleosides and methods for their use in DNA sequencing.
44. **Metzker ML**, Weier CA (2015) PCT WO2015/157747. Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications.
45. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2016) US Patent 9,399,798. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing; to be issued Jul 26, 2016.
46. **Metzker ML**, Weier CA (2016) US Patent Application Publication No. 15/122,543. Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications; filed Aug 30, 2016.
47. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2016) European Patent 2 125 856 B1. Photocleavable labeled nucleotides and nucleosides and labeled nucleotides and nucleosides for their use in DNA sequencing.
48. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2017) US Patent 9,689,035. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
49. **Metzker ML**, Weier CA (2017) PCT Application No. PCT/US2017/036129. Target reporter constructs and uses thereof; filed Jun 6, 2017.
50. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2017) US Patent 9,689,035. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
51. Litosh V, Stupi B, Hersh M, Wu W, **Metzker ML**. (2017) European Patent 2 307 565 B1. Reversible nucleosides and nucleotides terminators and their use in DNA sequencing.

52. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2018) US Patent 10,041,115. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
53. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2020) European Patent EP 2 755 984 B1. 5-Methoxy. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
54. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2021) US Patent 11,001,886. 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing.
55. **Metzker ML**, Weier CA (2021) European Patent EP 3 129 505 B1. Methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications.
56. Stupi B, Li H, Wu W, Hersh MN, Hertzog D, Morris SE, **Metzker ML**. (2021) European Patent EP 3 670 523 B1. 5-Methoxy. 3'-OH unblocked, fast photocleavable terminating nucleotides and their use in methods for nucleic acid sequencing.
57. **Metzker ML**, Weier CA (2022) U.S. Patent No. 11,299,769. Target reporter constructs and uses thereof.
58. **Metzker ML**, Weier CA (2022) U.S. Patent Application No. 17/702,152. Target reporter constructs and uses thereof, filed Mar 23, 2022.
59. **Metzker ML**, Weier CA (2024) European Patent Application EP 4 372 102. Target reporter constructs and uses thereof.

III. Teaching Information:

a. Courses taught at BCM:

- | | |
|--------------|--|
| 2000-to-2018 | <i>Molecular Methods</i> : All first-year graduate students are required to take this course. Three lectures taught: <i>cDNA and Genomic Libraries</i> , <i>First-generation Sequencing and Genotyping</i> , and <i>Next-generation Sequencing</i> . |
| 2001-to-2003 | <i>Mammalian Genetics</i> : All first-year genetics student are required to take this class. One lecture taught: <i>Mammalian Genome Analysis</i> . |

b. Graduate student training:

- | | |
|--------------|---|
| 2008-to-2011 | Major advisor for Diane Scaduto, graduated with PhD from CMB program |
| 2007-to-2010 | Thesis committee member for Rocio Benabentos, CMB program |
| 2004-to-2006 | Major advisor for Michele Sexton, graduated with MS degree from CMB program |
| 2001-to-2007 | Major advisor for Wade C. Haaland, graduated with PhD from CMB program |
| 2001-to-2005 | Thesis committee member for Teresa Venezia, graduated with PhD from CMB program |
| 2001-to-2013 | Qualifying examination reviewer for 1-2 Genetics & CMB students 2000-to-2013
First year student rotations (1-2 per year) |

c. Post-doctoral training:

2001-to-2003	Mathew Mahindaratne, Ph.D., now at UT San Antonio
2003-to-2004	Ernest Lewis, Ph.D., now at Rice University
2003-to-2006	Ming Fa, Ph.D.

d. Minority undergraduate student internships:

Summer 2004	Lamin Bangura, now at Ross University Medical School in Dominica(Caribbean)
Summer 2005	Rosalie Bangura, now at BCM
2006-to-2007	Demetra Farley, now in graduate school at Southwestern Medical Center, Division of Basic Science Program- Cancer Biology training track (began 2007)
Summer 2006	Mindy Smith, now at Chicago Medical School of Rosalind Franklin University of Medicine and Science
Summer 2006	Quincy Johnson, now at Texas A&M University Graduate School of Engineering (began 2007)
Summer 2007	Dionne Watson, student at Prairie View A&M University
Summer 2008	Nicholas Chambers, student at Prairie View A&M University
Summer 2009	Ogechi Nwaobia, student at University of Texas, Austin
Summer 2010	Brian Tenner, Southern Methodist University and Crist Cuffee, Virginia Polytechnic Institute and State University
2010-to-2013	Jesse Muniz, University of Texas at Brownsville graduate, B.S. Biology

e. Innovation Norway in Houston internships

Spring 2011	Liv Arnica Forberg Hovland, now Editorial Assistant/Senior Adviser for the Tax Directorate
Spring 2015	Stian A. Weiseth, Norwegian University of Life Sciences, Master of Science student in Innovation and Entrepreneurship
Spring 2015	Hanne Hansen, Bergen University College, Master of Science student in Innovation and Entrepreneurship
Spring 2016	Espen Svendsen, Bergen University College, Master of Science student in Innovation and Entrepreneurship
Spring 2016	Ingrid-Helen Liabø,, Norwegian University of Life Sciences, Master of Science student in Innovation and Entrepreneurship
Spring 2017	Axel William Nilsen, Norwegian University of Life Sciences, Master of Science student in Innovation and Entrepreneurship

f. Local lectures

Jun 2008	Repeat of DNA Day Celebration Lecture for high school students, organized by the Office of Diversity and Community Outreach's Office of Diversity and Community Outreach at BCM
Apr 2008	DNA Day Celebration Lecture for high school students, organized by the Office of Diversity and Community Outreach at BCM

IV. Service information:

Administrative assignment:

2002-to-2013 Member: BCM Patent and Copyright Committee

2007-to-2013 Member: HGSC New Faculty Search Committee